Compare APLE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | CRNX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2007 | 2018 |
| Metric | APLE | CRNX |
|---|---|---|
| Price | $16.55 | $35.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $13.00 | ★ $76.75 |
| AVG Volume (30 Days) | ★ 2.3M | 850.3K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,238,622,000.00 | $1,039,000.00 |
| Revenue This Year | $2.31 | $720.10 |
| Revenue Next Year | $2.35 | $184.67 |
| P/E Ratio | $137.79 | ★ N/A |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $25.83 |
| 52 Week High | $16.71 | $57.99 |
| Indicator | APLE | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 78.13 | 51.40 |
| Support Level | $11.50 | $33.15 |
| Resistance Level | N/A | $44.89 |
| Average True Range (ATR) | 0.34 | 1.56 |
| MACD | 0.04 | 0.33 |
| Stochastic Oscillator | 94.59 | 79.51 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.